- 3TC (lamivudine, Epivir)
- Abacavir (Ziagen)
- Atazanavir (Reyataz)
- Atripla
- AZT (zidovudine, Retrovir)
- Combivir
- d4T (stavudine, Zerit)
- Darunavir (Prezista)
- ddI (didanosine, Videx / VidexEC)
- Efavirenz (Sustiva)
- Fosamprenavir (Telzir)
- FTC (emtricitabine, Emtriva)
- Indinavir (Crixivan)
- Kaletra
- Kivexa
- Lopinavir
- Nelfinavir (Viracept)
- Nevirapine (Viramune)
- Ritonavir (Norvir)
- Saquinavir (Invirase)
- T-20 (enfuvirtide, Fuzeon)
- Tenofovir disoproxil (Viread)
- Tipranavir (Aptivus)
- Trizivir
- Truvada
Lopinavir
Lopinavir is a protease inhibitor that is manufactured by Abbott Laboratories. Protease inhibitors block the activity of the HIV protease (or proteinase) enzyme to slow HIV replication and delay damage to the immune system. During development, lopinavir was known as ABT-378.
Lopinavir must be taken with a low dose of ritonavir (Norvir), to slow the body’s processing of lopinavir boosts blood levels of the drug. This enhances the antiviral effect of lopinavir. Since Abbott manufactures both lopinavir and ritonavir, lopinavir is only available in combination with ritonavir. This combination is marketed as Kaletra.
For more information on lopinavir and Kaletra, see Kaletra.
latest aidsmap news
- Case report - viral load undetectable in blood, but detectable in semen
- 'Hidden epidemic' of HIV amongst African migrants in the United States
- Blood viral load predicts HIV transmission better than semen viral load in small study among MSM
- Infectiousness and antiretroviral therapy: reports look set to further fuel the debate
- Albendazole treatment of helminth co-infection in Kenyan HIV patients raises CD4 counts
- Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions'
- HIV prevalence and incidence in Uganda on the way up
- Half of Russian XDR-TB patients cured with aggressive treatment
- Updated British HIV pregnancy guidelines published
- Incidence increasing of HIV-associated multicentric Castleman's disease, a relatively rare lymphatic cancer
